MORRIS PLAINS, N.J., Dec. 19, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA) has issued a positive opinion on the Company's application for orphan designation of yttrium-90 labeled hPAM4 for the treatment of pancreatic cancer.
